LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Large neutral amino acid transporter 1 (LAT1) is a solute carrier protein located primarily in the blood-brain barrier (BBB) that offers the potential to deliver drugs to the brain. It is also up-regulated in cancer cells, as part of a tumor’s increased metabolic demands. Previously, amino acid prodrugs have been shown to be transported by LAT1. Carboxylic acid bioisosteres may afford prodrugs with an altered physicochemical and pharmacokinetic profile than those derived from natural amino acids, allowing for higher brain or tumor levels of drug and/or lower toxicity. The effect of replacing phenylalanine’s carboxylic acid with a tetrazole, acylsulfonamide and hydroxamic acid (HA) bioisostere was examined. Compounds were tested for their ability to be LAT1 substrates using both cis-inhibition and trans-stimulation cell assays. As HA-Phe demonstrated weak substrate activity, its structure-activity relationship (SAR) was further explored by synthesis and testing of HA derivatives of other LAT1 amino acid substrates (i.e. Tyr, Leu, Ile, and Met). The potential for a false positive in the trans-stimulation assay caused by parent amino acid was evaluated by conducting compound stability experiments for both HA-Leu and the corresponding methyl ester derivative. We concluded that HA’s are transported by LAT1. In addition, our results lend support to a recent account that amino acid esters are LAT1 substrates, and that hydrogen bonding may be as important as charge for interaction with the transporter binding site.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 4F2hc/LAT1 complex transports l-DOPA across the blood–brain barrier
Kageyama, T., Nakamura, M., Matsuo, A., Yamasaki, Y., Takakura, Y., Hashida, M., Kanai, Y., Naito, M., Tsuruo, T., Minato, N., et al. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02758-x · Cited by 298
The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
Barrett, S. D., Bridges, A. J., Dudley, D. T., Saltiel, A. R., Fergus, J. H., Flamme, C. M., Delaney, A. M., Kaufman, M., LePage, S., Leopold, W. R., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.054 · Cited by 289
Cited by
Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics
Kanai, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107964 · Cited by 283
Scalise, M., Galluccio, M., Console, L., Pochini, L., & Indiveri, C. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00243 · Cited by 281
Groeneweg, S., van Geest, F. S., Peeters, R. P., Heuer, H., & Visser, W. E. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz008 · Cited by 216
Krause, G., & Hinz, K. M. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.03.018 · Cited by 27
Describing inhibitor specificity for the amino acid transporter LAT1 from metainference simulations
Hutchinson, K., Silva, D. B., Bohlke, J., Clausen, C., Thomas, A. A., Bonomi, M., & Schlessinger, A. (2022) · Biophysical Journal · doi:10.1016/j.bpj.2022.11.001 · Cited by 18
Self-citation
Metadata
- Authors
- Zur, A. A., Chien, H.-C., Augustyn, E., Flint, A., Heeren, N., Finke, K., Hernandez, C., Hansen, L., Miller, S., Lin, L., Giacomini, K. M., Colas, C., Schlessinger, A., & Thomas, A. A.
- Venue
- Bioorganic & Medicinal Chemistry Letters
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 26
- Issue
- 20
- Pages
- 5000-5006
- ISSN
- 0960-894X (ISSN-L)
- OpenAlex
- W2516729291
- Cited by
- 46
- References
- 2
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.